Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Becker, JC; Ugurel, S; Bröcker, EB; Schrama, D; Houben, R.
New therapeutic approaches for solid tumors: histone deacetylase, methyltransferase and proteasome inhibitors.
J Dtsch Dermatol Ges. 2006; 4(2):108-113
Doi: 10.1111/j.1610-0387.2006.05920.x
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Becker Jürgen Christian
- Co-Autor*innen der Med Uni Graz
- Schrama David
- Ugurel-Becker Selma
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Recent results from basic and translational research on tumor genesis and progression establish the basis for future therapeutic approaches. Targeted therapeutics are tailored toward the molecular abnormalities that cause tumor progression and could potentially provide an effective, non-toxic therapeutic approach in a broad range of cancers including melanoma. Cancer is as much a (cyto)genetic disease as it is an epigenetic disease. Indeed, the fate of the cell depends on a delicate balance between expression and repression of genes. The notion that drastic changes in DNA methylation and histone modifications are present in a variety of human tumors has prompted the development and characterization of epigenetic drugs. Inhibitors of histone deacetylases and methyltransferases as well as of the proteasome are covered in this review.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents - therapeutic use
- Cell Transformation, Neoplastic - drug effects
- DNA Modification Methylases -
- Histone Deacetylase Inhibitors -
- Humans -
- Melanoma - drug therapy Melanoma - genetics
- Methyltransferases - antagonists and inhibitors
- Proteasome Endopeptidase Complex - antagonists and inhibitors
- Skin Neoplasms - drug therapy Skin Neoplasms - genetics